Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod PH20 SC in Bullous Pemphigoid
NCT05267600Phase 3Completed
- Sponsor
- argenx
- Start
- Jun 2022
- Primary completion
- Sep 2024
- Modality
- Antibody Fragments
- Countries
- 21
01
Overview
A Phase 3 trial of efgartigimod alfa in Bullous Pemphigoid (BP), sponsored by argenx. Started Jun 2022; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on NCT05267600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05267600.